| Autor: |
Jatuworapruk, Kanon, Montgomery, Anna, Gianfrancesco, Milena, Conway, Richard, Durcan, Laura, Graef, Elizabeth R., Jayatilleke, Aruni, Keen, Helen, Kilian, Adam, Young, Kristen, Carmona, Loreto, Cogo, Adriana Karina, Duarte‐García, Alí, Gossec, Laure, Hasseli, Rebecca, Hyrich, Kimme L., Langlois, Vincent, Lawson‐Tovey, Saskia, Malcata, Armando, Mateus, Elsa F |
| Předmět: |
|
| Zdroj: |
ACR Open Rheumatology; Nov2022, Vol. 4 Issue 11, p948-953, 6p |
| Abstrakt: |
Objective: To describe people with gout who were diagnosed with coronavirus disease 2019 (COVID‐19) and hospitalized and to characterize their outcomes. Methods: Data on patients with gout hospitalized for COVID‐19 between March 12, 2020, and October 25, 2021, were extracted from the COVID‐19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID‐19 outcomes including oxygenation or ventilation support and death. Results: One hundred sixty‐three patients with gout who developed COVID‐19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre‐COVID‐19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID‐19‐related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities. Conclusion: This cohort of people with gout and COVID‐19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID‐19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text